Gabexate
From Wikipedia, the free encyclopedia
 |
|
|
Gabexate
|
|
| Systematic (IUPAC) name | |
| ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C16H23N3O4 |
| Mol. mass | 311.37 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Gabexate mesilate or gabexate is a serine protease inhibitor which is used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation[1], and as a regional anticoagulant for haemodialysis.[2]
[edit] References
- ^ Yuksel M, Okajima K, Uchiba M, Okabe H (2003). "Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes". J. Pharmacol. Exp. Ther. 305 (1): 298–305. doi:. PMID 12649382.
- ^ Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V (1996). "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group". N. Engl. J. Med. 335 (13): 919–23. PMID 8786777.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
